A Phase 3 interventional study of Povorcitinib in Hidradenitis Suppurativa (HS), sponsored by Incyte Corporation. Active, not recruiting at 165 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-25.
Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Hidradenitis Suppurativa by Incyte Corporation — 3 open to participants now, 6 under way, 4 of them phase 3. Hidradenitis Suppurativa · Incyte Corporation.
Among the 12 studies in Hidradenitis Suppurativa by Incyte Corporation, this one is the 2nd largest by enrollment, is the only one that started in 2024, is one of 6 in phase 3, and was the 7th registered.
285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.
Browse Hidradenitis Suppurativa studies →3 of the 12 studies in Hidradenitis Suppurativa by Incyte Corporation are open now, in 12 countries. Recruiting first, the newest first:
Incyte Corporation · Sites in United States, Canada
Ages 12–17
Incyte Corporation · Sites in United States
Ages 12–75
Incyte Corporation · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
By country, each count listing its studies:
Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 617 is above the median of 45 across 200 interventional studies indexed under Hidradenitis Suppurativa.
Median enrollment 391 across the 12 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
2 of the studies in Hidradenitis Suppurativa by Incyte Corporation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06212999Phase 3Incyte CorporationA Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12-26 |
| NCT07049575Incyte CorporationStudy to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa | 2026-12-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Hidradenitis Suppurativa by Incyte Corporation, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 [NCT05620823] or INCB 54707-302 [NCT05620836]).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Povorcitinib at the protocol-defined dose strength based on cohort assignment.
Drug: Povorcitinib
Povorcitinib at the protocol-defined dose strength based on cohort assignment.
Drug: Povorcitinib
Povorcitinib at the protocol-defined dose strength based on cohort assignment.
Drug: Povorcitinib
Oral; Tablet
Also known as: INCB054707
Proportion of participants with Treatment-Emergent Adverse Events (TEAEs)
TEAE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug-related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug.
Time frame: up to approximately 56 weeks
Proportion of participants with Serious Treatment-Emergent Adverse Events (TEAEs)
Serious TEAE is defined as any untoward medical occurrence that, at any dose, meet at least one of the following criteria: (a) results in death; (b) is life-threatening; (c) requires inpatient hospitalization or prolongation of existing hospitalization; (d) results in persistent or significant disability/incapacity; (e) is a congenital anomaly/birth defect; (f) is an important medical event.
Time frame: up to approximately 56 weeks
Proportion of participants with TEAEs leading to study drug discontinuation
Defined as any TEAE that leads to discontinuation of study drug.
Time frame: up to approximately 56 weeks
Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response (HiSCR)
HiSCR is defined as at least a 50% reduction from baseline of parent study in the total abscess and inflammatory nodule (AN) count, with no increase from baseline of parent study in abscess or draining tunnel count.
Time frame: up to approximately 56 weeks
Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)
HiSCR75 is defined as at least a 75% reduction from baseline of parent study in the total AN count, with no increase from baseline of parent study in abscess or draining tunnel count.
Time frame: up to approximately 56 weeks
Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response 90 (HiSCR90)
HiSCR90 is defined as at least a 90% reduction from baseline of parent study in the total AN count, with no increase from baseline of parent study in abscess or draining tunnel count.
Time frame: up to approximately 56 weeks
Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response 100 (HiSCR100)
HiSCR100 is defined as a 100% reduction from baseline of parent study in the total AN count, with no increase from baseline of parent study in abscess or draining tunnel count.
Time frame: up to approximately 56 weeks
Proportion of participants with flare at each visit
Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 ANs relative to Week 54.
Time frame: up to approximately 56 weeks
Time to first flare
Time to first flare during the long-term extension study.
Time frame: up to approximately 56 weeks
Mean change from baseline of parent study in Hidradenitis Suppurativa Quality of Life (HiSQoL) score at each visit
The HiSQoL is a HS-specific, health-related quality of life (QoL) instrument. The HiSQoL total score ranges from 0 to 68, with higher scores indicating higher disease impact on QoL.
Time frame: up to approximately 56 weeks
Mean change from baseline of parent study in Dermatology Life Quality Index (DLQI) score at each visit
The DLQI is a skin disease specific questionnaire aimed at the evaluation of how symptoms and treatment affect participants' health-related quality of life (QoL). The DLQI total score ranges from 0 to 30, with higher scores indicating lower skin health related QoL.
Time frame: up to approximately 56 weeks
Proportion of participants with no increase in abscess and inflammatory nodule (AN) count relative to Week 54 at each visit
Time frame: up to approximately 56 weeks
Proportion of participants with no increase in abscess, inflammatory nodule, and draining tunnel (ANdT) count relative to Week 54 at each visit
ANdT count is defined as the total sum of abscesses, inflammatory nodules, and draining tunnels.
Time frame: up to approximately 56 weeks
Proportion of participants with no increase in draining tunnel count relative to Week 54 at each visit
Time frame: up to approximately 56 weeks
Proportion of participants with a total AN count of 0, 1, or 2 at each visit
AN count defined as the total sum of abscesses and inflammatory nodules.
Time frame: up to approximately 56 weeks
Proportion of participants with a total ANdT count of 0, 1, or 2 at each visit
ANdT count is defined as the total sum of abscesses, inflammatory nodules, and draining tunnels.
Time frame: up to approximately 56 weeks
Showing the first 100 of 165 sites across 17 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Data sharing details ↗ · www.incyte.com
Started Jan 2024 (actual). Primary completion is estimated for Dec 2026, 34 months after the start.
Of 26 phase 3 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's planned 34 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Povorcitinib